Differential allelic expression in leukoblast from patients with acute myeloid leukemia suggests genetic regulation of CDA, DCK, NT5C2, NT5C3, and TP53

Drug Metabolism and Disposition

Volumn 36, Issue 12, 2008, Pages 2419-2423

  Jordheim, Lars P ^a,b,d   Nguyen Dumont, T ^a   Thomas, X ^c   Dumontet, C ^b   Tavtigian, S V ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b UNIVERSITÉ DE LYON   (France)

^c EDOUARD HERRIOT HOSPITAL   (France)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; CYTARABINE; CYTIDINE DEAMINASE; DEOXYCYTIDINE KINASE; NUCLEOTIDE TRANSPORTER; PROTEIN P53;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BIOINFORMATICS; CONTROLLED STUDY; GENE EXPRESSION; GENETIC REGULATION; GENOTYPE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 57349152158     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.023184     Document Type: Article

References (18)

1. Abraham J, Earl HM, Pharoah PD, and Caldas C (2006) Pharmacogenetics of cancer chemotherapy. Biochim Biophys Acta 1766:168-183.
2. Crockett AO and Wittwer CT (2001) Fluorescein-labeled oligonucleotides for real-time pcr: using the inherent quenching of deoxyguanosine nucleotides. Anal Biochem 290:89-97.
3. Fitzgerald SM, Goyal RK, Osborne WR, Roy JD, Wilson JW, and Ferrell RE (2006) Identification of functional single nucleotide polymorphism haplotypes in the cytidine deaminase promoter. Hum Genet 119:276-283.
4. Gilbert JA, Salavaggione OE, Ji Y, Pelleymounter LL, Eckloff BW, Wieben ED, Ames MM, and Weinshilboum RM (2006) Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin Cancer Res 12:1794-1803.
5. Joerger M, Bosch TM, Doodeman VD, Beijnen JH, Smits PH, and Schellens JH (2006) Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers. Eur J Clin Pharmacol 62:681-684.
6. Jordheim LP and Dumontet C (2007) Review of recent studies on resistance to cytotoxic deoxynucleoside analogues. Biochim Biophys Acta 1776:138-159.
7. Marinaki AM, Escuredo E, Duley JA, Simmonds HA, Amici A, Naponelli V, Magni G, Seip M, Ben-Bassat I, Harley EH, et al. (2001) Genetic basis of hemolytic anemia caused by pyrimidine 5′ nucleotidase deficiency. Blood 97:3327-3332.
8. Milani L, Gupta M, Andersen M, Dhar S, Fryknäs M, Isaksson A, Larsson R, and Syvänen AC (2007) Allelic imbalance in gene expression as a guide to cis-acting regulatory single nucleotide polymorphisms in cancer cells. Nucleic Acids Res 35:e34.
9. Myers SN, Goyal RK, Roy JD, Fairfull LD, Wilson JW, and Ferrell RE (2006) Functional single nucleotide polymorphism haplotypes in the human equilibrative nucleoside transporter 1. Pharmacogenet Genomics 16:315-320.
10. Osato DH, Huang CC, Kawamoto M, Johns SJ, Stryke D, Wang J, Ferrin TE, Herskowitz I, and Giacomini KM (2003) Functional characterization in yeast of genetic variants in the human equilibrative nucleoside transporter, ENT1. Pharmacogenetics 13:297-301.
11. Pastinen T and Hudson TJ (2004) Cis-acting regulatory variation in the human genome. Science 306:647-650.
12. Reed GH and Wittwer CT (2004) Sensitivity and specificity of single-nucleotide polymorphism scanning by high-resolution melting analysis. Clin Chem 50:1748-1754.
13. Shi JY, Shi ZZ, Zhang SJ, Zhu YM, Gu BW, Li G, Bai XT, Gao XD, Hu J, Jin W, et al. (2004) Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients. Pharmacogenetics 14:759-768.
14. Stamatoyannopoulos JA (2004) The genomics of gene expression. Genomics 84:449-457.
15. Sugiyama E, Kaniwa N, Kim SR, Kikura-Hanajiri R, Hasegawa R, Maekawa K, Saito Y, Ozawa S, Sawada J, Kamatani N, et al. (2007) Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J Clin Oncol 25:32-42.
16. Ware MD, DeSilva D, Sinilnikova OM, Stoppa-Lyonnet D, Tavtigian SV, and Mazoyer S (2006) Does nonsense-mediated mRNA decay explain the ovarian cancer cluster region of the BRCA2 gene? Oncogene 25:323-328.
17. Wasserman WW and Sandelin A (2004) Applied bioinformatics for the identification of regulatory elements. Nat Rev Genet 5:276-287.
18. Wilkins JM, Southam L, Price AJ, Mustafa Z, Carr A, and Loughlin J (2007) Extreme context specificity in differential allelic expression. Hum Mol Genet 16:537-546.